Aubrey de Grey: 2018 was a fantastic year for rejuvenation biotechnology. The main thing that made it special was the explosive growth of the private-sector side of the field – the number of startup companies, the number of investors, and the scale of investment. 2 companies, AgeX Therapeutics and Unity Biotechnology, went public with 9-digit valuations, and a bunch of others are not far behind. Of course this has only been possible because of all the great progress that has been made in the actual science, but one can never predict when that slow, steady progress will reach “critical mass”.
2020-06-16: Towards the mainstream
within 3-5 years there will be a rapid shift in public expectation in longevity. The lab and clinical research will get to the point that experts will be willing to say radical longevity is achievable. Major media will then trumpet it. The public will then change their beliefs.
Gregor J. Rothfuss 